1 Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012.CA Cancer J Clin,2015,65:87-108. 2 Plummer M,de Martel C,Vignat J,et al.Global burden of cancers attributable to infections in 2012:a synthetic analysis.Lancet Glob Health,2016,4:e609-e616. 3 Kudela E,Holubekova V,Farkasova A,et al.Determination of malignant potential of cervical intraepithelial neoplasia.Tumour Biol,2016,37:1521-1525. 4 Munger K,Baldwin A,Edwards KM,et al.Mechanisms of human papillomavirus-induced oncogenesis.J Virol,2004,78:11451-11460. 5 Graham SV,Faizo AA.Control of human papillomavirus gene expression by alternative splicing.Virus Res,2017,231:83-95. 6 Zanier K,Ould MOSA,Boulade-Ladame C,et al.Solution structure analysis of the HPV16 E6 oncoprotein reveals a self-association mechanism required for E6-mediated degradation of p53.Structure,2012,20:604-617. 7 Schiffman M,Wentzensen N.From human papillomavirus to cervical cancer.Obstet Gynecol,2010,116:177-185. 8 Fontecha N,Basaras M,Hernaez S,et al.Assessment of human papillomavirus E6/E7 oncogene expression as cervical disease biomarker.BMC Cancer,2016,16:852. 9 Duvlis S,Popovska-Jankovic K,Arsova ZS,et al.HPV E6/E7 mRNA versus HPV DNA biomarker in cervical cancer screening of a group of Macedonian women.J Med Virol,2015,87:1578-1586. 10 Alaghehbandan R,Fontaine D,Bentley J,et al.Performance of ProEx C and PreTect HPV-Proofer E6/E7 mRNA tests in comparison with the hybrid capture 2 HPV DNA test for triaging ASCUS and LSIL cytology.Diagn Cytopathol,2013,41:767-775. 11 Shen Y,Gong J,He Y,et al.Quantivirus(R) HPV E6/E7 RNA 3.0 assay (bDNA) is as sensitive,but less specific than Hybrid Capture 2 test.J Virol Methods,2013,187:288-293. 12 Monsonego J,Hudgens MG,Zerat L,et al.Risk assessment and clinical impact of liquid-based cytology,oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study).Gynecol Oncol,2012,125:175-180. 13 Practice Bulletin No.168 Summary:Cervical Cancer Screening and Prevention.Obstet Gynecol,2016,128:923-925. 14 Rodriguez AC,Schiffman M,Herrero R,et al.Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections.J Natl Cancer Inst,2008,100:513-517. 15 Liu TY,Xie R,Luo L,et al.Diagnostic validity of human papillomavirus E6/E7 mRNA test in cervical cytological samples.J Virol Methods,2014,196:120-125. 16 Monsonego J,Hudgens MG,Zerat L,et al.Risk assessment and clinical impact of liquid-based cytology,oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study).Gynecol Oncol,2012,125:175-180. 17 Haedicke J,Iftner T.A review of the clinical performance of the Aptima HPV assay.J Clin Virol,2016,76 Suppl 1:S40-S48. 18 Cook DA,Smith LW,Law J,et al.Aptima HPV Assay versus Hybrid Capture(R) 2 HPV test for primary cervical cancer screening in the HPV FOCAL trial.J Clin Virol,2017,87:23-29. 19 Zhao H,Shao H.Diagnostic value of human papillomavirus E6/E7 mRNA for residue and recurrence after cervical conization.Zhong Nan Da Xue Xue Bao Yi Xue Ban,2016,41:606-611. 20 Anderson LA.Prophylactic human papillomavirus vaccines:past,present and future.Pathology,2012,44:1-6. 21 Committee Opinion No.704:Human Papillomavirus Vaccination.Obstet Gynecol,2017,129:1155-1156. 22 Sayour EJ,Mitchell DA.Manipulation of Innate and Adaptive Immunity through Cancer Vaccines.J Immunol Res,2017,2017:3145742. 23 Diken M,Kranz LM,Kreiter S,et al.mRNA:A Versatile Molecule for Cancer Vaccines.Curr Issues Mol Biol,2017,22:113-128. 24 Dell K,Klein C,Gissmann L.Comparison of DNA- and mRNA-transfected mouse dendritic cells as potential vaccines against the human papillomavirus type 16 associated oncoprotein E7.Antivir Ther,2008,13:495-509.
